Sunshine Biopharma, Inc.
SBFM
Rank in Stocks
#30148
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of... Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Share Price
$2.75
Last synced: 2026-11-09
Market Cap
$5.84M
Change (1 day)
1.48%
Change (1 year)
-84.46%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sunshine Biopharma, Inc. (SBFM)
Category
Healthcare
EPS for Sunshine Biopharma, Inc. (SBFM)
EPS as of June 2026 TTM: $-203.00
According to Sunshine Biopharma, Inc.'s latest financial reports, its current EPS (TTM) is $-203.00. At the end of 2025 the company had an EPS of $-288.00, an increase over its 2024 EPS of $-1.46K.
EPS history for Sunshine Biopharma, Inc. from 2007 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-203.00 | -29.51% |
| 2025 | $-288.00 | -80.33% |
| 2024 | $-1.46K | -97.92% |
| 2023 | $-70.27K | -90.03% |
| 2022 | $-704.73K | -63.95% |
| 2021 | $-1.95M | 204.03% |
| 2020 | $-642.98K | -82.96% |
| 2019 | $-3.77M | 13,186.58% |
| 2018 | $-28.40K | 495.64% |
| 2017 | $-4.77K | -85.52% |
| 2016 | $-32.93K | -99.99% |
| 2015 | $-330.58M | 314,039.54% |
| 2014 | $-105.23K | -36.39% |
| 2013 | $-165.44K | 200.05% |
| 2012 | $-55.14K | 20.74% |
| 2011 | $-45.67K | -34.91% |
| 2010 | $-70.15K | 0.00% |
| 2009 | 0.00 | -100.00% |
| 2008 | $-13.29K | 137.02% |
| 2007 | $-5.61K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -103.20% |
DE
|
|
| $6.08 | -102.99% |
DE
|
|
| $1.55 | -100.76% |
JP
|
|
| $3.66 | -101.80% |
CH
|
|
| $0.45 | -100.22% |
IL
|
Questions about Sunshine Biopharma, Inc.'s earnings per share (EPS)
What is Sunshine Biopharma, Inc.'s earnings per share (EPS)?
Sunshine Biopharma, Inc.'s earnings per share (EPS) over the last twelve months is $-203.00, as of Jun 2026.
What was Sunshine Biopharma, Inc.'s earnings per share (EPS) in 2025?
In 2025, Sunshine Biopharma, Inc.'s earnings per share (EPS) was $-288.00, compared with $-1.46K in 2024.
How has Sunshine Biopharma, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Sunshine Biopharma, Inc.'s earnings per share (EPS) was highest in 2025 ($-288.00) and lowest in 2021 ($-1.95M).
How does Sunshine Biopharma, Inc.'s earnings per share (EPS) compare with similar companies?
Sunshine Biopharma, Inc.'s earnings per share (EPS) ($-203.00) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.